Health
Novartis Acquires Myricx Bio
Novartis is acquiring Myricx Bio for $1.1 billion, expanding its antibody-drug conjugate development efforts.
Coverage timeline — 1 article
STAT News
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
2026-07-06 12:56 UTC